Summary:
With M Gravis halting the progression is a big deal and evidence of metabolic improvement gives encouragement.
Conditions:
Tests Ordered:
Age:
Gender:
Date:
myasthenia gravis
K91 Urine Organix Profile
58
F
3/24/2004
History
At initial evaluation the patient was unable to lift herself off of the examination table to stand up. She had been placed on several medications to treat Myasthenia gravis, including Prednisone, Imuran, Mestinon, Detrol, Paxil, Benedril, Prempro, Protonix and Tums. After the initial test profile, supplemental multiple essential amino acids, Coenzyme Q10, and B-complex vitamins were added. Calcium Hydroxyapetite was given along with Uc Sustain and Probiotics.
After the second profile, the mixed amino acid powder was discontinued and arginine was started because of the indication of overloading of urea cycle. The other major change at this time was Candibactin use to bring intestinal fungal growth under control. Supplementation with CoQ10 was increased, and amino acid support was shifted from mixed EAA to specific arginine and carnitine. She has been feeling much more energetic, and her enthusiasm has resulted in significant efforts for dietary improvement.
At the end of the second year, a third Organix profile was done. The patient was so greatly improved that she regularly participated in Pilates classes and her medication dosages had been dramatically reduced: Protonix discontinued, Prednisone 80 --> 5mg, Mestinon 180 mg/day --> 150 mg/day, off Tums and Prempro. She is extremely encouraged, and she continues to work on dietary improvement along with her devotion to Pilates classes.
Description of Results
The first Organix profile revealed significant intestinal bacterial and yeast overgrowth along with indications for Coenzyme Q10 and thiamin. Low lactate is generally found in patients with poor amino acid flux through hepatic pathways.
The one year follow up profile included several new metabolic markers, so we now pick up evidence of folate (FIGLU) and antioxidant (8OHdG) insufficiency. Increased flux of amino acids through hepatic pathways raises the sensitivity of the cofactor metabolic markers. Thus we now see orotate elevation and two keto acids high, showing need to continue repletion doses. Another new marker, quinolinate, is found elevated, indicating the ongoing inflammatory process.
At two years, indications for folate and oxidative challenge are greatly reduced, while the lactate has normalized and other CoQ10 indicators, succinate, fumarate, and malate are significantly lower. Quinolinate is now almost within normal limits, and orotate has normalized. No yeast markers are high, although bacterial overgrowth continues to be significant.
The following bone density improvements were recorded shortly after additional major dietary improvements and new excercise routines were begun in 2004:
Jan 2002 Lumbar 2.3 std. below normal
Jan 2002 Left Hip 1.8 std. below normal
Jan2004 Lumbar 2.14 std. below normal
Jan 2004 Left hip 1.7 std. below normal
Recommendations
Continue efforts to normalize intestinal health by application of probiotic therapies and use of digestive aids. Re-emphasize the need for thiamin support as this area shows such persistent signs that it suggests genetic polymorphic dependency may be present, dictating life-long high level supplementation.
Other Comments
The progression of laboratory data shows the time scale needed for optimization of metabolic efficiencies and intestinal health in such a chronic, progressive disorder. The very favorable clinical response confirms the efficacy of such optimization in halting the progression of myasthenia gravis.
© 2008 Metametrix, Inc. All rights reserved.